| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 5,950 | 6,400 | 20:10 |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 35,000 | 6 | |||
| 33,000 | 33 | |||
| 22,200 | 30 | |||
| 16,000 | 500 | |||
| 15,000 | 15 | |||
| 6,400 | 1.564 | |||
| 6,350 | 500 | |||
| 6,300 | 728 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/88q.htm [/URL] | ||||
| 728 | 6,000 | |||
| 1.564 | 5,950 | |||
| 700 | 4,740 | |||
| 1.061 | 0,001 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 4.053 | 0,833 | 3.376 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
Keine Umsätze verfügbar. | ||
| Tagesumsatz Xetra | 0,000 0,00 % | 0 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 22.07. | 4basebio Plc - Grant of Options & Director/PDMR Dealing | 320 | PR Newswire | 4basebio Plc - Grant of Options & Director/PDMR Dealing
PR Newswire
LONDON, United Kingdom, July 22
4basebio PLC
("4basebio"... ► Artikel lesen | |
| 4BASEBIO Aktie jetzt für 0€ handeln | |||||
| 08.07. | 4basebio Plc - Director Appointment | 546 | PR Newswire | 4basebio Plc - Director Appointment
PR Newswire
LONDON, United Kingdom, July 08
4basebio PLC
("4basebio" or the "Company")
... ► Artikel lesen | |
| 30.06. | 4basebio Plc - Result of AGM & Issue of Options | 378 | PR Newswire | 4basebio Plc - Result of AGM & Issue of Options
PR Newswire
LONDON, United Kingdom, June 30
4basebio PLC
("4basebio"... ► Artikel lesen | |
| 16.06. | 4basebio Plc - Notice of Investor Presentation | 380 | PR Newswire | 4basebio Plc - Notice of Investor Presentation
PR Newswire
LONDON, United Kingdom, June 16
4basebio... ► Artikel lesen | |
| 15.06. | IN BRIEF: 4basebio appoints Jeff Coller to Strategic Advisory Board | 1 | Alliance News |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| Do | Myriad Genetics, Inc.: Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Productivity and Scalability | GlobeNewswire (Europe) | Highlights Second quarter 2026 revenue of $190.7 million decreased 11% year-over-year, reflecting a 1% decline in volume and a 9% decrease in average revenue per test year-over-year. The company is... ► Artikel lesen | |
| 17:12 | Weekly Buzz: Cipla, Viatris Win FDA Nod; Boston Scientific Cuts Jobs; argenx Snaps Up Forte Biosciences; Johnson & Johnson, GSK Strike Deals | AFX News | NEW BRUNSWICK (dpa-AFX) - The healthcare sector delivered another eventful week, marked by major regulatory approvals, strategic partnerships, acquisitions, restructuring initiatives and significant... ► Artikel lesen | |
| 14:48 | Morning Market Movers: Replimune Group, BioAge Labs, T3 Defense, AXT, Inc. See Big Swings | AFX News | BEIJING (dpa-AFX) - At 8:15 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| 15:45 | Moderna dämpft die Kosten, kämpft aber weiter mit hohen Verlusten | 4investors | Moderna hat im zweiten Quartal 2026 einen Umsatz von 145 Millionen US-Dollar erzielt, nach 142 Millionen US-Dollar im Vorjahresquartal. Rückläufige COVID-Impfstoffverkäufe in den USA und Südamerika... ► Artikel lesen | |
| 13:06 | Tenax Therapeutics, Inc.: Tenax Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update | GlobeNewswire (Europe) | Company expects to report topline data from Phase 3 LEVEL clinical trial in August 2026 CHAPEL HILL, N.C., July 31, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) ("Tenax" or "Tenax... ► Artikel lesen |